Satellos Bioscience Inc Com V.ICO

RE:The Gold Report update to ICO and new recommendation

[pp19888]

Gold report article about ico!!!!!!
The second recommendation came on iCo Therapeutics (TSXV: ICO) on April 17th at 0.035 with a 1-year target of $0.20, although the stock traded at a low of 4 cents on that day after the report came out. While the company has never officially announced any takeover interest from Immune Pharmaceuticals (IMNP) nor any other company, research suggests that it is a strong possibility. Even if it doesn't happen, the company has $5.4 million in net tangible liquid assets in cash and IMNP shares, or about 6.5 cents per ICO share. ICO's annual report came out on April 27th and when comparing to Q3 results, the working capital position improved due to the grant received from the government for the Amp B oral delivery system which was used to offset research expenses. ICO has also pulled back from a high of 13.5 cents due to normal profit-taking and is bouncing around in the 8 to 10 cent range. The Gold Report suggests that 7 cents would be an absolute low for those who wish to buy shares and that serious selling shouldn't take place until 20 cents. Very little upside is priced into the stock given its relative safety as a TSXV junior with a strong working capital position and shares in a NASDAQ stock. Given its strong cash balance and that IMNP is doing all the work on Bertilimumab/iCO-008, ICO is looking for further investment opportunities in biotech and healthcare. ICO has been a company focused on eye diseases and we know that marijuana is known for the treatment of glaucoma...so put two and two together on that one.